360DigitalInfluence

Next week Ogilvy will be sharing our point of view when it comes to how pharmaceutical and medical device brands should be allowed to use the web and social media for marketing and promotion. This has been a significant gray area in the past and the FDA has begun the process towards having some updated guidelines set. We are one of over 60 organizations that will be speaking during the two day hearing next week, and the questions will range from everything to what information marketers should be allowed to link to, and how they should be held responsible for content online.

The biggest question that the entire process will raise is how to define the content, messages and conversations online that marketers should be held accountable by the FDA for. To answer this top question, we will be presenting our point of view through “The 3 C’s Rule” …

What do you think - does this “rule” go too far, or far enough towards helping define what messages marketers should be accountable for online? For more context, check our our full FDA presentations on Slideshare:

http://www.slideshare.net/ogilvypharma